UB Paderborn / Katalog / Suche / in CDI

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

Critical care (London, England), 2017-09, Vol.21 (1), p.234-234, Article 234

2017

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers

Chest, 2017-03, Vol.151 (3), p.555-563

2017

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor

British journal of clinical pharmacology, 2016-05, Vol.81 (5), p.971-979

2016

Link zum Volltext

Verfügbarkeit prüfen

Predictors of Objective Cough Frequency in Chronic Obstructive Pulmonary Disease

American journal of respiratory and critical care medicine, 2013-05, Vol.187 (9), p.943-949

2013

Link zum Volltext

Verfügbarkeit prüfen

SB‐656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone‐induced airway inflammation in humans

British journal of clinical pharmacology, 2011-08, Vol.72 (2), p.282-293

2011

Link zum Volltext

Verfügbarkeit prüfen

Plasma sTNFR1 and IL8 for prognostic enrichment in sepsis trials: a prospective cohort study

Critical care (London, England), 2019-12, Vol.23 (1), p.400-400, Article 400

2019

Link zum Volltext

Verfügbarkeit prüfen

The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma

Respiratory research, 2010-03, Vol.11 (1), p.26-26, Article 26

2010

Link zum Volltext

Verfügbarkeit prüfen

Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD

Pulmonary pharmacology & therapeutics, 2013-10, Vol.26 (5), p.588-595

2013

Link zum Volltext

Verfügbarkeit prüfen

Elevated Airway Purines in COPD

Chest, 2011-10, Vol.140 (4), p.954-960

2011

Link zum Volltext

Verfügbarkeit prüfen

Discovering Drugs with DNA‐Encoded Library Technology: From Concept to Clinic with an Inhibitor of Soluble Epoxide Hydrolase

Chembiochem : a European journal of chemical biology, 2017-05, Vol.18 (9), p.837-842

2017

Link zum Volltext

Verfügbarkeit prüfen

CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin

ERJ open research, 2020-10, Vol.6 (4), p.583

2020

Link zum Volltext

Verfügbarkeit prüfen

Study to Explore the Association of the Renin-Angiotensin System and Right Ventricular Function in Mechanically Ventilated Patients

Journal of clinical medicine, 2022-07, Vol.11 (15), p.4362

2022

Link zum Volltext

Verfügbarkeit prüfen

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects

BMC pharmacology & toxicology, 2015-06, Vol.16 (1), p.18, Article 18

2015

Link zum Volltext

Verfügbarkeit prüfen

An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension

Pulmonary circulation, 2022-01, Vol.12 (1), p.e12024-n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

Assessment of potential drug interactions by characterization of human drug metabolism pathways using non‐invasive bile sampling

British journal of clinical pharmacology, 2013-02, Vol.75 (2), p.488-496

2013

Link zum Volltext

Verfügbarkeit prüfen

Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD

The European respiratory journal, 2018-10, Vol.52 (4), p.1801020

2018

Link zum Volltext

Verfügbarkeit prüfen

Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660)

British journal of clinical pharmacology, 2017-12, Vol.83 (12), p.2813-2820

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis

Journal of cystic fibrosis, 2013-05, Vol.12 (3), p.241-248

2013

Link zum Volltext

Verfügbarkeit prüfen

Investigating the effect of TRPV4 inhibition on pulmonary-vascular barrier permeability following segmental endotoxin challenge

Pulmonary pharmacology & therapeutics, 2020-10, Vol.64, p.101977-101977, Article 101977

2020

Link zum Volltext

Verfügbarkeit prüfen

A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome

Critical care medicine, 2015-09, Vol.43 (9), p.1859-1869

2015

Link zum Volltext

Verfügbarkeit prüfen

Airway smooth muscle: A modulator of airway remodeling in asthma

Journal of allergy and clinical immunology, 2005-09, Vol.116 (3), p.488-495

2005

Link zum Volltext

Verfügbarkeit prüfen

Identification and characterisation of a salt form of Danirixin with reduced pharmacokinetic variability in patient populations

European journal of pharmaceutics and biopharmaceutics, 2017-08, Vol.117, p.224-231

2017

Link zum Volltext

Verfügbarkeit prüfen

Mast Cell Chymase Modifies Cell-Matrix Interactions and Inhibits Mitogen-Induced Proliferation of Human Airway Smooth Muscle Cells

The Journal of immunology (1950), 2002-07, Vol.169 (2), p.1014-1020

2002

Link zum Volltext

Verfügbarkeit prüfen

A nebulised antitumour necrosis factor receptor-1 domain antibody in patients at risk of postoperative lung injury: A randomised, placebo-controlled pilot study

European journal of anaesthesiology, 2020-11, Vol.37 (11), p.1014-1024

2020

Link zum Volltext

Verfügbarkeit prüfen

Impaired muscle mitochondrial density and/or function: a COPD-specific mitochondropathy or simply deconditioning?

The European respiratory journal, 2012-11, Vol.40 (5), p.1070-1071

2012

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers

Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor

Predictors of Objective Cough Frequency in Chronic Obstructive Pulmonary Disease

SB‐656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone‐induced airway inflammation in humans

Plasma sTNFR1 and IL8 for prognostic enrichment in sepsis trials: a prospective cohort study

The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma

Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD

Elevated Airway Purines in COPD

Discovering Drugs with DNA‐Encoded Library Technology: From Concept to Clinic with an Inhibitor of Soluble Epoxide Hydrolase

CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin

Study to Explore the Association of the Renin-Angiotensin System and Right Ventricular Function in Mechanically Ventilated Patients

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects

An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension

Assessment of potential drug interactions by characterization of human drug metabolism pathways using non‐invasive bile sampling

Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD

Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660)

Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis

Investigating the effect of TRPV4 inhibition on pulmonary-vascular barrier permeability following segmental endotoxin challenge

A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome

Airway smooth muscle: A modulator of airway remodeling in asthma

Identification and characterisation of a salt form of Danirixin with reduced pharmacokinetic variability in patient populations

Mast Cell Chymase Modifies Cell-Matrix Interactions and Inhibits Mitogen-Induced Proliferation of Human Airway Smooth Muscle Cells

A nebulised antitumour necrosis factor receptor-1 domain antibody in patients at risk of postoperative lung injury: A randomised, placebo-controlled pilot study

Impaired muscle mitochondrial density and/or function: a COPD-specific mitochondropathy or simply deconditioning?

Suchergebnisse filtern